What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
Mario Boccadoro mostly deals with Multiple myeloma, Surgery, Internal medicine, Bortezomib and Transplantation.
His studies deal with areas such as Autologous transplantation and Chemotherapy as well as Multiple myeloma.
His studies in Surgery integrate themes in fields like Thalidomide, Dexamethasone and Hazard ratio.
His Internal medicine research integrates issues from Gastroenterology and Oncology.
Mario Boccadoro interconnects Proteasome inhibitor, Urology, Survival rate and Adverse effect, Pharmacology in the investigation of issues within Bortezomib.
In his study, which falls under the umbrella issue of Transplantation, Risk factor is strongly linked to Survival analysis.
His most cited work include:
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management (484 citations)
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial (364 citations)
- Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial (279 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Multiple myeloma, Oncology, Surgery and Transplantation.
In most of his Internal medicine studies, his work intersects topics such as Gastroenterology.
His research in Multiple myeloma tackles topics such as Bone marrow which are related to areas like Cancer research.
His research in Oncology intersects with topics in Hematology, Clinical trial, Carfilzomib and Daratumumab.
His Lenalidomide study combines topics in areas such as Maintenance therapy and Autologous stem-cell transplantation.
The Thalidomide study combines topics in areas such as Adverse effect, Pharmacology and Salvage therapy.
He most often published in these fields:
- Internal medicine (63.28%)
- Multiple myeloma (58.55%)
- Oncology (29.90%)
What were the highlights of his more recent work (between 2018-2021)?
- Multiple myeloma (58.55%)
- Internal medicine (63.28%)
- Oncology (29.90%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Multiple myeloma, Internal medicine, Oncology, Newly diagnosed and Clinical trial.
His work carried out in the field of Multiple myeloma brings together such families of science as Intensive care medicine, Maintenance therapy, Transplantation and Minimal residual disease.
Lenalidomide, Dexamethasone, Carfilzomib, Bortezomib and Hematology are the core of his Internal medicine study.
His Bortezomib study integrates concerns from other disciplines, such as Thalidomide and Melphalan.
The concepts of his Oncology study are interwoven with issues in Ixazomib, Relapsed refractory, Randomized controlled trial and Pomalidomide.
In his study, Toxicity is strongly linked to Gastroenterology, which falls under the umbrella field of Newly diagnosed.
Between 2018 and 2021, his most popular works were:
- Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma. (85 citations)
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study (58 citations)
- Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial. (48 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Multiple myeloma, Internal medicine, Oncology, Lenalidomide and Clinical trial are his primary areas of study.
His Multiple myeloma research is multidisciplinary, incorporating elements of Intensive care medicine and Minimal residual disease.
His study in Oncology is interdisciplinary in nature, drawing from both Cell therapy and MRD Negativity.
His biological study spans a wide range of topics, including Treatment goals, Chimeric antigen receptor, Progression-free survival and Bone marrow.
Mario Boccadoro focuses mostly in the field of Bortezomib, narrowing it down to matters related to Transplantation and, in some cases, Polypharmacy and Watchful waiting.
Mario Boccadoro works mostly in the field of Hazard ratio, limiting it down to topics relating to Regimen and, in certain cases, Thalidomide, Phases of clinical research and Intention-to-treat analysis, as a part of the same area of interest.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
